Ticker Details
Corbus Pharmaceuticals Holdings, Inc. Common Stock Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
IPO Date:	November 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$210.29M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 3.83%
Avg Daily Range (30 D):	$0.32 | 3.09%
Avg Daily Range (90 D):	$0.29 | 3.17%

Institutional Daily Volume
Avg Daily Volume:	1.12M
Avg Daily Volume (30 D):	.29M
Avg Daily Volume (90 D):	.21M

Trade Size
Avg Trade Size (Sh.):	233
Avg Trade Size (Sh.) (30 D):	82
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	449
Avg Institutional Trade:	$1.76M
Avg Institutional Trade (30 D):	$.93M
Avg Institutional Trade (90 D):	$.93M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.06M
Avg Closing Trade (30 D):	$2.13M
Avg Closing Trade (90 D):	$2.13M
Avg Closing Volume:	45.81K

News

May 13, 2026 @ 11:00 AM Corbus Pharmaceuticals to Participate in Upcoming ... Source: Not Specified

May 12, 2026 @ 12:00 PM Corbus Pharmaceuticals Reports Q1 2026 Financial R... Source: Not Specified

Feb 12, 2026 @ 1:00 PM Corbus Pharmaceuticals to Present at the 36th Annu... Source: Not Specified

Oct 31, 2025 @ 6:40 AM Corbus Pharmaceuticals Announces Pricing of Public... Source: Globe Newswire

Oct 31, 2025 @ 6:40 AM Corbus Pharmaceuticals Announces Pricing of Public... Source: Sean Moran

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-5.74	$-1.23	$-1.17
Diluted EPS	$-5.74	$-1.23	$-1.17
Revenue	$5.25M	$1.4M	$1.41M
Gross Profit
Net Income / Loss	$-84.53M	$-22.97M	$-20.56M
Operating Income / Loss	$-89.84M	$-24.3M	$-21.97M
Cost of Revenue
Net Cash Flow	$11.29M	$M	$1.51M
PE Ratio

Splits
Feb 14, 2023	1:30